Second Supp. Preliminary Amendment &

Response to Restriction Requirement dated October 12, 2007

Reply to Office Action (Restriction Requirement) of September 27, 2007

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (withdrawn): A cell for expressing serotonin (5HT) isolated from a human NT2 cell line.

Claim 2 (original): A cell for expressing gamma-aminobutyric acid (GABA) isolated from a human NT2 cell line.

Claim 3 (withdrawn): A cell for expressing serotonin (5HT) cloned from a cell obtained from a human NT2 cell line.

Claim 4 (original): A cell for expressing gamma-aminobutyric acid (GABA) cloned from a cell obtained from a human NT2 cell line.

Second Supp. Preliminary Amendment &

Response to Restriction Requirement dated October 12, 2007

Reply to Office Action (Restriction Requirement) of September 27, 2007

Claim 5 (withdrawn): A method of treating a neurological disease, condition, or disorder, comprising:

administering to a subject in need thereof a suitable amount of serotonin (5HT) expressing hNT2 cells.

Claim 6 (withdrawn): The method of Claim 5, wherein:

the hNT2 cells are transplanted in or adjacent to the spinal cord of the subject.

Claim 7 (withdrawn): The method of Claim 5, wherein:

the hNT2 cells are transplanted in or adjacent to the brain of the subject.

Claim 8 (withdrawn): The method of Claim 5, wherein:

the hNT2 cells are transplanted at a location in or adjacent to the central or peripheral nervous system of the subject.

Second Supp. Preliminary Amendment &

Response to Restriction Requirement dated October 12, 2007

Reply to Office Action (Restriction Requirement) of September 27, 2007

Claim 9 (currently amended): A method of treating a neurological disease, condition, or disorder, comprising:

administering to a subject in need thereof a suitable amount of <u>at least one</u> member selected from the group consisting of a cell transplant material, gamma-aminobutyric acid (GABA) expressing hNT2 cells, <u>and a combination thereof</u>.

Claim 10 (original): The method of Claim 9, wherein:

the hNT2 cells are transplanted in or adjacent to the spinal cord of the subject.

Claim 11 (original): The method of Claim 9, wherein:

the hNT2 cells are transplanted in or adjacent to the brain of the subject.

Claim 12 (original): The method of Claim 9, wherein:

the hNT2 cells are transplanted at a location in or adjacent the central or peripheral nervous system of the subject.

Second Supp. Preliminary Amendment &

Response to Restriction Requirement dated October 12, 2007

Reply to Office Action (Restriction Requirement) of September 27, 2007

Claim 13 (original): A composition for treating a neurological disease, condition, or disorder, comprising:

- a) a cell for expressing a bioagent selected from the group consisting of serotonin (5HT), and gamma-aminobutyric acid (GABA), the cell having been isolated from a human NT2 cell line; and
- b) a suitable carrier.

Claim 14 (original): The composition of Claim 13, wherein:

a) the neurological disease, condition, or disorder comprises one or more of pain, spasticity, epilepsy, depression, mobility disorder, sensory disorder, Parkinson's, or Alzheimer's disease.

Claim 15 (original): A composition for treating a neurological disease, condition, or disorder, comprising:

- a) a cell expressing a bioagent selected from the group consisting of serotonin (5HT), and gamma-aminobutyric acid (GABA), the cell having been cloned from a cell obtained from a human NT2 cell line; and
- b) a suitable carrier.

Second Supp. Preliminary Amendment &

Response to Restriction Requirement dated October 12, 2007

Reply to Office Action (Restriction Requirement) of September 27, 2007

Claim 16 (original): The composition of Claim 15, wherein:

a) the neurological disease, condition, or disorder comprises one or more of

pain, spasticity, epilepsy, depression, mobility disorder, sensory disorder,

Parkinson's, or Alzheimer's disease.

Claim 17 (withdrawn): A method of producing a mammal useful for studying a

neurological disease, condition, and/or disorder, comprising:

transplanting a suitable amount of serotonin expressing human NT2 cells into or

near a mammal's spinal cord, brain, or peripheral nervous system.

Claim 18 (withdrawn): The method of Claim 17, wherein the mammal is a rodent.

Claim 19 (withdrawn): A rodent produced in accordance with the method of Claim 17.

Claim 20 (withdrawn): A method of producing a mammal useful for studying a

neurological disease, condition, or disorder, comprising:

transplanting a suitable amount of gamma-aminobutyric acid (GABA) expressing

human NT2 cells into or near a mammal's spinal cord, brain, or peripheral nervous

system.

Second Supp. Preliminary Amendment &

Response to Restriction Requirement dated October 12, 2007

Reply to Office Action (Restriction Requirement) of September 27, 2007

Claim 21 (withdrawn): The method of Claim 20, wherein the mammal is a rodent.

Claim 22 (withdrawn): A rodent produced in accordance with the method of Claim 20.

Claim 23 (withdrawn): A cell transplant material, comprising:

a) serotonin expressing human NT2 cells.

Claim 24 (cancelled).

Claim 25 (withdrawn): A cell for expressing serotonin (5HT) deposited with the American Type Culture Collection (ATCC) Manassas, Virginia (USA), under Designation No. PTA-7153.

Claim 26 (cancelled).

Claim 27 (new): The cell of Claim 2, wherein:

the cell comprises a cell deposited with the American Type Culture Collection (ATCC) Manassas, Virginia (USA), under Designation No. PTA-7154.

Appl. No.: 10/553,291
Second Supp. Preliminary Amendment &
Response to Restriction Requirement dated October 12, 2007
Reply to Office Action (Restriction Requirement) of September 27, 2007

Claim 28 (new): The cell of Claim 4, wherein:

the cell comprises a cell deposited with the American Type Culture Collection (ATCC) Manassas, Virginia (USA), under Designation No. PTA-7154.

Claim 29 (new): The method of Claim 9, wherein:

the cell transplant material comprises gamma-aminobutyric acid (GABA) expressing human NT2 cells.